Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

QEL-001

PreclinicalSmall molecule

QQuell Therapeutics Limited

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Rejection; Transplant, LiverActive, not recruiting

Rejection; Transplant, LiverPreclinical

Active, not recruiting

Timeline

Expected Milestones

Q3 2040

PreclinicalActive, not recruiting

Rejection; Transplant, Liver

NCT05234190

Clinical

Trials by Indication[1]

Rejection; Transplant, Liver1 trial

A Single-arm, Open-label, Multi-center, Phase I/II Study Evaluating the Safety and Clinical Activity of QEL-001, an Autologous CAR T Regulatory Cell Treatment Targeting HLA-A2, in HLA-A2/ A28neg Patients That Have Received an HLA-A2pos Liver Transplant.

Active, not recruiting·QQuell Therapeutics Limited·Preclinical·NCT05234190·33 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for QEL-001. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — QEL-001 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for QEL-001. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Quell Therapeutics Limited company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: QQuell Therapeutics Limited

Related News